In the largest and most conclusive study of its kind, researchers have analysed blood samples to create a novel and non-invasive way of helping to diagnose Alzheimer’s disease and distinguish between different types of neurodegenerative disorders.
Following this breakthrough discovery, Alzheimer’s sufferers may now have an additional test to improve the accuracy of diagnosis in order to better tailor appropriate treatment.
The research also offers a valuable opportunity to monitor the progression of the disease.
The international study in the Proceedings of the National Academy of Sciences USA used sensor-based technology with a diamond core to analyse approximately 550 blood samples.
By passing light through the diamond and observing its interactions with the blood plasma, researchers were able to identify specific chemical bonds within the blood. This biochemical data was used to compare blood samples from cases of Alzheimer’s disease and other neurodegenerative diseases with those from healthy controls.
The ground-breaking scientific investigation was carried out by researchers at Lancaster University, the University of Central Lancashire (UCLan), the University of Manchester and the Federal University of Rio Grande do Norte, Brazil.
Professor David Allsop from Lancaster University has been collaborating for many years withProfessor David Mann from the University of Manchester in searching for diagnostic markers for neurodegenerative disease in blood plasma.
They provided all of the plasma samples for the study, along with supporting clinical and genetic information, and expertise in Alzheimer’s and other neurodegenerative conditions.
Professor Allsop said: “A particularly exciting aspect of the study was the ability to distinguish accurately between Alzheimer’s disease and Lewy body dementia, which are conditions that both result in dementia and can be difficult to separate from each other based on clinical information and symptoms. By reduction of misdiagnosed cases and administration of appropriate treatment, many people could benefit from this type of blood test in the future.”
Alzheimer’s diagnosis currently involves careful medical evaluation including clinical history, memory testing and brain scans, yet the only conclusive diagnosis is determined by post-mortem examination. This new blood test offers a non-invasive, more accurate and relatively cost-effective method of diagnosis, which will ensure the correct management of the condition.
Professor Francis Martin, principal investigator of the study and Biosciences theme lead at UCLan, said: “We have an aging population, meaning that the incidence and prevalence of Alzheimer’s is increasing, as is the need for accurate diagnosis. The ability to identify different neurodegenerative diseases through the analysis of blood offers a faster and accurate way of establishing the most effective treatment plan as well as disease monitoring.”
This new approach could also offer potential for carrying out tests to identify and monitor early signs of mild cognitive impairment, meaning that the onset of Alzheimer’s and other types of neurodegenerative diseases could be detected early and intervention measures could be put in place earlier to slow the progress of these diseases.
Professor Martin added: “For those suffering with Alzheimer’s disease, the damage is already well advanced once conventionally diagnosed, but this new method offers a potentially effective early screening tool when patients are only demonstrating signs of mild cognitive impairment. This is a potentially significant breakthrough for the prevention of different debilitating and chronic neurological diseases.”
The Latest on: Alzheimer’s
- In Alzheimer’s, New Protein Is Seen at Heart of Plaque Formationon January 22, 2020 at 2:41 pm
Details about the discovery of FAM22A appeared January 21 in the journal Nature Communications, in an article entitled, “FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease.” ...
- Pharma company gets $2.7M grant to continue 'positive' Alzheimer's treatment trialson January 22, 2020 at 2:11 pm
Could hope finally be on the horizon for patients diagnosed with Alzheimer’s disease? Continue Reading Below Biopharmaceutical company Neurotrope announced on Wednesday that its latest trial of ...
- Some Great News for Potential Alzheimer’s Treatmenton January 22, 2020 at 12:20 pm
Neurotrope released a corporate update after analyzing data from its recently reported Phase 2 confirmatory clinical trial examining moderately severe to severe Alzheimer's disease patients.
- Aluminum in brain tissue could increase risk for familial Alzheimer'son January 22, 2020 at 8:24 am
While recent studies have assessed the genetic component of Alzheimer’s, a new study has determined yet another way that family history can play a role in the condition. The researchers found that ...
- How To Make A Difference In The Fight Against Alzheimer’son January 22, 2020 at 6:26 am
By Arnaud Bernaert, Head of Shaping the Future of Health and Health Care, World Economic Forum Alzheimer’s disease is uniquely devastating. It destroys a person’s memories and cognitive capabilities, ...
- Navy women’s basketball to honor legendary Tennessee coach Pat Summitt, raise awareness for Alzheimer’son January 22, 2020 at 3:12 am
“We Back Pat" is an initiative rooted in the Pat Summitt Foundation in which various women’s basketball teams sign up and host a game during the week of January 19 to honor the trailblazing coach and ...
- Study first to show pharmacological chaperone therapy prevents Alzheimer's in miceon January 22, 2020 at 1:31 am
Now, scientists at the Lewis Katz School of Medicine at Temple University show that pharmacological chaperones could fill a critical role in Alzheimer's disease therapy. In a new study published ...
- Suppression of newly found protein could lead to future treatments to slow Alzheimer's progressionon January 22, 2020 at 12:34 am
Researchers at the Case Western University School of Medicine say they have identified a previously unknown gene and associated protein which could potentially be suppressed to slow the advance of ...
- Readers sound off on the Improving HOPE for Alzheimer’s Act, Lev Parnas, and Meghan and Harry’s moveon January 22, 2020 at 12:00 am
Alexandria Ocasio-Cortez has said health care is one of the very basic needs to sustain modern life that should be guaranteed in a moral society. Alzheimer’s, the most expensive disease in the United ...
- Possible Alzheimer's breakthrough suggestedon January 21, 2020 at 4:00 pm
Researchers say they have identified a previously unknown gene and associated protein (which they have named 'aggregatin') which could potentially be suppressed to slow the advance of Alzheimer's ...
via Google News and Bing News